Literature DB >> 20694301

Progression to overweight, obesity and associated factors after antiretroviral therapy initiation among Brazilian persons with HIV/AIDS.

L H Maia Leite1, A B De Mattos Marinho Sampaio.   

Abstract

OBJECTIVES: To assess body weight changes, progression to overweight/obesity and investigate the associated factors among HIV/AIDS patients.
METHODS: A retrospective study was conducted involving a sample group of 203 adults with HIV/AIDS. Medical records were used to gather demographic, clinical and anthropometric information. The variables were compared by Chi-square tests, Student's t tests and One-way analysis of variance.
RESULTS: The majority of the individuals studied were men (72.4%) with an average age of 34.68 +/- 8.3 years, and time of HIV infection of 4.12 +/- 1.8 years. 63% of the patients gained weight. The greatest weight gain was observed among patients with lower CD4 cell count on admission (8.45 +/- 6.6 vs. 5.97 +/- 4.97) p = 0.019. 39/203 new cases of overweight/obesity were identified, with a progression rate of 19%. Men were more likely to progress to overweight (p < 0.001) and women to obesity (p < 0.001). A direct and significant relationship was observed between the BMI level on admission and being overweight/obese at the end of the study for individuals admitted with normal weight.
CONCLUSIONS: The results of the study show that in the course of HIV infection overweight/obesity affected men and women admitted with normal weight, although a greater proportion of women progressed to obesity. A higher weight gain contributed in a negative manner to the presence of dyslipidemias in these patients. These data show the importance of monitoring body weight in the course of HIV/AIDS treatment, even in those individuals who present normal body weight.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20694301

Source DB:  PubMed          Journal:  Nutr Hosp        ISSN: 0212-1611            Impact factor:   1.057


  11 in total

1.  Prevalence and Risk Factors for Overweight and Obesity among HIV-Infected Adults in Dar es Salaam, Tanzania.

Authors:  Helen Semu; Rachel M Zack; Enju Liu; Ellen Hertzmark; Donna Spiegelman; Kevin Sztam; Claudia Hawkins; Guerino Chalamila; Aisa Muya; Hellen Siril; Ramadhani Mwiru; Deo Mtasiwa; Wafaie Fawzi
Journal:  J Int Assoc Provid AIDS Care       Date:  2014-08-21

2.  Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.

Authors:  Kassem Bourgi; Peter F Rebeiro; Megan Turner; Jessica L Castilho; Todd Hulgan; Stephen P Raffanti; John R Koethe; Timothy R Sterling
Journal:  Clin Infect Dis       Date:  2020-03-17       Impact factor: 9.079

3.  Inflammation and Change in Body Weight With Antiretroviral Therapy Initiation in a Multinational Cohort of HIV-Infected Adults.

Authors:  Vidya Mave; Kristine M Erlandson; Nikhil Gupte; Ashwin Balagopal; David M Asmuth; Thomas B Campbell; Laura Smeaton; Nagalingeswaran Kumarasamy; James Hakim; Breno Santos; Cynthia Riviere; Mina C Hosseinipour; Patcharaphan Sugandhavesa; Rosa Infante; Sandy Pillay; Sandra W Cardoso; Srikanth Tripathy; Noluthando Mwelase; Sima Berendes; Bruno B Andrade; David L Thomas; Robert C Bollinger; Amita Gupta
Journal:  J Infect Dis       Date:  2016-03-08       Impact factor: 5.226

4.  Severe food insecurity is associated with overweight and increased body fat among people living with HIV in the Dominican Republic.

Authors:  Kathryn P Derose; Israel Ríos-Castillo; María Altagracia Fulcar; Denise D Payán; Kartika Palar; Lisbeth Escala; Hugo Farías; Homero Martínez
Journal:  AIDS Care       Date:  2017-07-06

Review 5.  Fat Matters: Understanding the Role of Adipose Tissue in Health in HIV Infection.

Authors:  Kristine M Erlandson; Jordan E Lake
Journal:  Curr HIV/AIDS Rep       Date:  2016-02       Impact factor: 5.071

6.  Treatment with a fixed dose combination antiretroviral therapy drug containing tenofovir, emtricitabine and efavirenz is associated with cardioprotection in high calorie diet-induced obese rats.

Authors:  Frans Everson; Amanda Genis; Temitope Ogundipe; Patrick De Boever; Nandu Goswami; Amanda Lochner; Dee Blackhurst; Hans Strijdom
Journal:  PLoS One       Date:  2018-12-05       Impact factor: 3.240

7.  Overweight and Obesity Among Adult HIV Infected Peoples Receiving ART in Ethiopia: A Systematic Review and Meta-Analysis.

Authors:  Robel Hussen Kabthymer; Solomon Nega Techane; Temesgen Muche; Helen Ali Ewune; Semagn Mekonnen Abate; Mohammed Feyisso Shaka
Journal:  J Prim Care Community Health       Date:  2021 Jan-Dec

8.  A Randomized Comparison of Anthropomorphic Changes With Preferred and Alternative Efavirenz-Based Antiretroviral Regimens in Diverse Multinational Settings.

Authors:  Kristine M Erlandson; Sineenart Taejaroenkul; Laura Smeaton; Amita Gupta; Isaac L Singini; Javier R Lama; Rosie Mngqibisa; Cynthia Firnhaber; Sandra Wagner Cardoso; Cecilia Kanyama; Andre L Machado da Silva; James G Hakim; Nagalingeswaran Kumarasamy; Thomas B Campbell; Michael D Hughes
Journal:  Open Forum Infect Dis       Date:  2015-06-24       Impact factor: 3.835

9.  Changes in Body Mass Index and Atherosclerotic Disease Risk Score After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide.

Authors:  Jason J Schafer; Kaitlin N Sassa; Jaclyn R O'Connor; Ayako Shimada; Scott W Keith; Joseph A DeSimone
Journal:  Open Forum Infect Dis       Date:  2019-10-04       Impact factor: 3.835

10.  Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.

Authors:  Kassem Bourgi; Cathy A Jenkins; Peter F Rebeiro; Frank Palella; Richard D Moore; Keri N Altoff; John Gill; Charles S Rabkin; Stephen J Gange; Michael A Horberg; Joseph Margolick; Jun Li; Cherise Wong; Amanda Willig; Viviane D Lima; Heidi Crane; Jennifer Thorne; Michael Silverberg; Gregory Kirk; William C Mathews; Timothy R Sterling; Jordan Lake; John R Koethe
Journal:  J Int AIDS Soc       Date:  2020-04       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.